A Study to Evaluate SSGJ-707 in Advanced Gynecologic Cancer Patients
Trial statusRecruiting
Trial phasePhase 2
Trial typeInterventional
Biological sexAll
Age18-75
SponsorSunshine Guojian Pharmaceutical (Shanghai) Co., Ltd.
About this trial
This is an open, multicenter Phase II clinical study of SSGJ-707 combined with chemotherapy in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer. The objective is to evaluate the safety, tolerability and antitumor activity of SSGJ-707 in the treatment of advanced/recurrent endometrial cancer and platinum-resistant ovarian cancer.
Eligibility criteria
Qualifiers
Age:18-75 years old
Advanced endometrial cancer and platinum-resistant ovarian cancer
Eastern Cooperative Oncology Group (ECOG) performance status of 0-1.
Expected survival >=12 weeks.
Disqualifiers
Known uncontrolled or symptomatic central nervous system metastatic disease.
Adverse events (with exception of alopecia and fatigue) from any prior anticancer therapy of grade >1 (National Cancer Institute Common terminology Criteria [NCI CTCAE] v.5.0).
Inadequate organ or bone marrow function.
Pregnant or breast-feeding woman.
Trial design
Treatments tested in this trial
- SSGJ-707
- carboplatin
- paclitaxel
Treatment groups
80 Participants
are divided into 4 treatment groupsSponsors and collaborators
Source ClinicalTrials.gov